JP6259463B2 - ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 - Google Patents
ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 Download PDFInfo
- Publication number
- JP6259463B2 JP6259463B2 JP2015541882A JP2015541882A JP6259463B2 JP 6259463 B2 JP6259463 B2 JP 6259463B2 JP 2015541882 A JP2015541882 A JP 2015541882A JP 2015541882 A JP2015541882 A JP 2015541882A JP 6259463 B2 JP6259463 B2 JP 6259463B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- mmol
- alkyl
- membered
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Dermatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723854P | 2012-11-08 | 2012-11-08 | |
| US61/723,854 | 2012-11-08 | ||
| PCT/US2013/068842 WO2014074660A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506368A JP2016506368A (ja) | 2016-03-03 |
| JP2016506368A5 JP2016506368A5 (enExample) | 2016-11-17 |
| JP6259463B2 true JP6259463B2 (ja) | 2018-01-10 |
Family
ID=49667568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541882A Active JP6259463B2 (ja) | 2012-11-08 | 2013-11-07 | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9315494B2 (enExample) |
| EP (1) | EP2922841B8 (enExample) |
| JP (1) | JP6259463B2 (enExample) |
| KR (1) | KR102233252B1 (enExample) |
| CN (1) | CN104781252B (enExample) |
| AR (1) | AR093403A1 (enExample) |
| AU (1) | AU2013341185B2 (enExample) |
| BR (1) | BR112015010244A8 (enExample) |
| CA (1) | CA2890929A1 (enExample) |
| EA (1) | EA028526B1 (enExample) |
| IL (1) | IL238554A0 (enExample) |
| MX (1) | MX2015005272A (enExample) |
| SG (1) | SG11201503396UA (enExample) |
| TW (1) | TWI620737B (enExample) |
| WO (1) | WO2014074660A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35126A (es) | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | Ojo es alfa |
| MX2015005561A (es) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa). |
| PE20150953A1 (es) * | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| CN105992768B (zh) | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| WO2016022626A1 (en) * | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP3313840B1 (en) | 2015-06-24 | 2019-07-24 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| KR102641263B1 (ko) | 2015-06-24 | 2024-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | 헤테로아릴 치환된 아미노피리딘 화합물 |
| CN108026099B (zh) | 2015-06-24 | 2020-07-10 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| KR102097878B1 (ko) * | 2015-11-26 | 2020-04-06 | 노파르티스 아게 | 디아미노 피리딘 유도체 |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| MA48602A (fr) * | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
| US10336752B2 (en) | 2017-03-08 | 2019-07-02 | Nimbus Lakshmi, Inc. | TYK2 inhibitors, uses, and methods for production thereof |
| TW201900640A (zh) | 2017-05-11 | 2019-01-01 | 美商必治妥美雅史谷比公司 | 作為irak4抑制劑之噻吩并吡啶及苯并噻吩 |
| TWI776810B (zh) * | 2017-05-12 | 2022-09-11 | 瑞士商諾華公司 | 新穎二胺基吡啶衍生物 |
| MY205416A (en) | 2017-07-28 | 2024-10-21 | Takeda Pharmaceuticals Co | Tyk2 inhibitors and uses thereof |
| JP7258903B2 (ja) * | 2017-11-21 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160875A1 (en) | 2018-02-13 | 2019-08-22 | Rutgers, The State University Of New Jersey | Antibacterial agents: soluble salts and aqueous formulations of pyronins |
| CN112118837B (zh) | 2018-02-13 | 2024-07-09 | 罗格斯新泽西州立大学 | 抗菌剂：o-烷基氘化派洛宁 |
| WO2019173507A1 (en) | 2018-03-06 | 2019-09-12 | Rutgers, The State University Of New Jersey | Antibacterial agents : arylalkylcarboxamido phloroglucinols |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| US12240840B2 (en) * | 2018-10-30 | 2025-03-04 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020154474A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020156311A1 (zh) * | 2019-01-28 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| KR20220035447A (ko) | 2019-07-18 | 2022-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물 |
| JP7573596B2 (ja) | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| EP4027995A4 (en) | 2019-09-13 | 2023-08-23 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND THEIR APPLICATIONS |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| JP7682191B2 (ja) | 2020-02-03 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環ヘテロアリール化合物 |
| CN112203515B (zh) * | 2020-03-11 | 2022-08-02 | 西北农林科技大学 | N-苄基苯甲酰胺类化合物作为除草剂的用途 |
| EP4136073A1 (en) * | 2020-04-14 | 2023-02-22 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| KR20230004771A (ko) | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| JP7537002B2 (ja) * | 2020-08-07 | 2024-08-20 | 南京薬石科技股▲フン▼有限公司 | Ｃｄｋ９阻害剤およびその使用 |
| CN114181257B (zh) * | 2020-09-14 | 2025-02-14 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物，包含其的药物组合物，其制备方法及其用途 |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN117098757A (zh) | 2021-02-02 | 2023-11-21 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022222470A1 (en) * | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| US20240189309A1 (en) * | 2021-02-19 | 2024-06-13 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022223497A1 (en) * | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| EP4319756A4 (en) | 2021-04-09 | 2025-02-26 | Nimbus Clio, Inc. | CBL-B MODULATORS AND USES THEREOF |
| CN119013277A (zh) | 2021-10-25 | 2024-11-22 | 凯麦拉医疗公司 | Tyk2降解剂和其用途 |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| TW202339749A (zh) * | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Ｔｙｋ２抑制劑及其組合物和方法 |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119585250A (zh) * | 2022-04-19 | 2025-03-07 | 蓝图药品公司 | Kit抑制剂 |
| EP4532485A1 (en) * | 2022-05-27 | 2025-04-09 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| KR20250057800A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도 |
| WO2024249855A1 (en) * | 2023-06-02 | 2024-12-05 | Idrx, Inc. | Combination therapy comprising kit inhibitors for use in the treatment of cancer |
| TW202529769A (zh) | 2023-09-21 | 2025-08-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JPWO2010058846A1 (ja) * | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| JP2014500254A (ja) | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
-
2013
- 2013-11-07 BR BR112015010244A patent/BR112015010244A8/pt not_active Application Discontinuation
- 2013-11-07 EA EA201590913A patent/EA028526B1/ru not_active IP Right Cessation
- 2013-11-07 KR KR1020157014693A patent/KR102233252B1/ko active Active
- 2013-11-07 SG SG11201503396UA patent/SG11201503396UA/en unknown
- 2013-11-07 US US14/441,193 patent/US9315494B2/en active Active
- 2013-11-07 AU AU2013341185A patent/AU2013341185B2/en not_active Ceased
- 2013-11-07 CA CA2890929A patent/CA2890929A1/en not_active Abandoned
- 2013-11-07 EP EP13795911.0A patent/EP2922841B8/en active Active
- 2013-11-07 WO PCT/US2013/068842 patent/WO2014074660A1/en not_active Ceased
- 2013-11-07 CN CN201380058022.7A patent/CN104781252B/zh active Active
- 2013-11-07 JP JP2015541882A patent/JP6259463B2/ja active Active
- 2013-11-07 MX MX2015005272A patent/MX2015005272A/es unknown
- 2013-11-07 TW TW102140570A patent/TWI620737B/zh not_active IP Right Cessation
- 2013-11-07 AR ARP130104094A patent/AR093403A1/es unknown
-
2015
- 2015-04-30 IL IL238554A patent/IL238554A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL238554A0 (en) | 2015-06-30 |
| JP2016506368A (ja) | 2016-03-03 |
| CN104781252A (zh) | 2015-07-15 |
| SG11201503396UA (en) | 2015-05-28 |
| MX2015005272A (es) | 2015-07-14 |
| CN104781252B (zh) | 2017-11-17 |
| KR102233252B1 (ko) | 2021-03-26 |
| WO2014074660A1 (en) | 2014-05-15 |
| KR20150081338A (ko) | 2015-07-13 |
| BR112015010244A8 (pt) | 2019-10-01 |
| EP2922841A1 (en) | 2015-09-30 |
| CA2890929A1 (en) | 2014-05-15 |
| AU2013341185A1 (en) | 2015-07-02 |
| EP2922841B1 (en) | 2017-06-07 |
| TW201422587A (zh) | 2014-06-16 |
| EA201590913A1 (ru) | 2015-10-30 |
| BR112015010244A2 (pt) | 2017-07-11 |
| EP2922841B8 (en) | 2017-08-02 |
| AR093403A1 (es) | 2015-06-03 |
| US9315494B2 (en) | 2016-04-19 |
| AU2013341185B2 (en) | 2017-07-13 |
| TWI620737B (zh) | 2018-04-11 |
| EA028526B1 (ru) | 2017-11-30 |
| US20150307483A1 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6259463B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 | |
| JP6585231B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 | |
| US9987266B2 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | |
| HK1226400B (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150805 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160928 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170817 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170822 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20171004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6259463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |